Clinical proof of principle for ChimeriVax™: recombinant live, attenuated vaccines against flavivirus infections

This publication has 32 references indexed in Scilit:

• Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine
  Journal of Virology, 2001
• Phylogenetic analysis suggests only one serotype of Japanese encephalitis virus
  Vaccine, 2000
• Recombinant, chimaeric live, attenuated vaccine (ChimeriVax™) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates
  Vaccine, 1999
• In Vivo Synthesis of Tumor Necrosis Factor‐α in Healthy Humans after Live Yellow Fever Vaccination
  The Journal of Infectious Diseases, 1998
• Immunogenicity of Live Attenuated SA14–14–2 Japanese Encephalitis Vaccine—A Comparison of 1–and 3‐Month Immunization Schedules
  The Journal of Infectious Diseases, 1998
• Yellow Fever Vaccines
  Biologicals, 1997
• Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study
  The Lancet, 1996
• Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines
  Vaccine, 1993
• Genetic Variation of Japanese Encephalitis Virus in Nature
  Journal of General Virology, 1990
• HEMAGGLUTINATION WITH ARTHROPOD-BORNE VIRUSES
  The Journal of Experimental Medicine, 1954